Rhumbline Advisers Phathom Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 55,178 shares of PHAT stock, worth $993,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,178

Previous 47,103 17.14%

Holding current value

$993,204

Previous $500,000 13.6%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$8.97 - $12.05 $72,432 - $97,303	8,075 Added 17.14%	55,178 $568,000
Q1 2024 May 09, 2024	SELL	$6.21 - $11.05 $8,687 - $15,458	-1,399 Reduced 2.88%	47,103 $500,000
Q4 2023 Feb 08, 2024	SELL	$6.99 - $10.71 $56,164 - $86,054	-8,035 Reduced 14.21%	48,502 $442,000
Q3 2023 Nov 09, 2023	BUY	$10.26 - $15.7 $64,966 - $99,412	6,332 Added 12.61%	56,537 $586,000
Q2 2023 Aug 08, 2023	BUY	$7.28 - $14.32 $126,992 - $249,798	17,444 Added 53.25%	50,205 $718,000
Q1 2023 May 11, 2023	BUY	$6.19 - $12.36 $12,559 - $25,078	2,029 Added 6.6%	32,761 $234,000
Q4 2022 Feb 14, 2023	BUY	$9.18 - $11.53 $16,569 - $20,811	1,805 Added 6.24%	30,732 $345,000
Q3 2022 Nov 10, 2022	BUY	$6.46 - $12.11 $14,715 - $27,586	2,278 Added 8.55%	28,927 $321,000
Q2 2022 Aug 11, 2022	BUY	$6.2 - $15.5 $41,422 - $103,555	6,681 Added 33.46%	26,649 $225,000
Q1 2022 May 12, 2022	BUY	$11.55 - $20.06 $31,889 - $55,385	2,761 Added 16.05%	19,968 $272,000
Q4 2021 Feb 10, 2022	SELL	$17.83 - $33.15 $4,404 - $8,188	-247 Reduced 1.42%	17,207 $338,000
Q3 2021 Nov 12, 2021	BUY	$30.69 - $36.83 $31,181 - $37,419	1,016 Added 6.18%	17,454 $560,000
Q2 2021 Aug 05, 2021	BUY	$32.66 - $39.87 $164,867 - $201,263	5,048 Added 44.32%	16,438 $556,000
Q1 2021 May 06, 2021	SELL	$33.86 - $48.68 $27,426 - $39,430	-810 Reduced 6.64%	11,390 $428,000
Q4 2020 Feb 10, 2021	BUY	$33.22 - $50.26 $42,521 - $64,332	1,280 Added 11.72%	12,200 $405,000
Q3 2020 Nov 12, 2020	SELL	$29.24 - $40.19 $54,678 - $75,155	-1,870 Reduced 14.62%	10,920 $400,000
Q2 2020 Aug 13, 2020	BUY	$25.06 - $54.6 $34,257 - $74,638	1,367 Added 11.97%	12,790 $421,000
Q1 2020 May 06, 2020	BUY	$24.65 - $42.83 $109,372 - $190,036	4,437 Added 63.51%	11,423 $295,000
Q4 2019 Feb 05, 2020	BUY	$18.59 - $37.67 $129,869 - $263,162	6,986 New	6,986 $218,000

Others Institutions Holding PHAT

# of Institutions

126

Shares Held

59.6M

Call Options Held

467K

Put Options Held

34.9K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $705M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Phathom Pharmaceuticals, Inc. Transaction History